Application and efficacy of ruxolitinib tablets/ruxolitinib in the treatment of blood diseases

Ruxolitinib tablets/Ruxolitinib is an effective JAK1 and JAK2 inhibitor that has been widely recognized and used to treat a variety of blood diseases. Ruxolitinib tablets have demonstrated excellent therapeutic efficacy in adult patients with myelofibrosis (MF), polycythemia vera (PVF), and graft-versus-host disease (cGVHD). Its effects are not only rapid but also long-lasting, can improve splenomegaly and other symptoms associated with myelofibrosis, and bring survival advantages to patients. However, to ensure optimal treatment efficacy, monitoring of blood cell counts and precise dosage adjustment are particularly important, as ruxolitinib tablets may cause dose-dependent cytopenias.

1. Myelofibrosis treatment:

In two large studies covering 528 patients, ruxolitinib tablets showed more significant efficacy than placebo, especially in reducing the size of the spleen. In the first six-month study, 42% of patients treated with ruxolitinib achieved the goal of 35% spleen shrinkage, compared with less than 1% of patients in the placebo group. The second study showed that after one year of treatment, 29% of patients treated with ruxolitinib tablets had a 35% reduction in spleen size, while none of the patients who received other optimal treatments achieved this effect.

2. Treatment of polycythemia vera:

In a pivotal study, ruxolitinib tablets successfully improved the conditions of 222 patients. These are patients whose prior treatment with hydroxyurea has failed or has experienced unacceptable side effects. The results of the study showed that after eight months of treatment, 21% of patients showed significant improvement, as measured by a reduction in the number of phlebotomy treatments and a shrinkage of the spleen by at least 35%. By comparison, only 1% of patients who received the other best treatments showed similar improvements.

3. Treatment of graft-versus-host disease: Ruxolitinib tablets also demonstrated effective relief of symptoms of acute and chronic graft-versus-host disease in two major studies.

In the first study involving 309 patients with acute graft-versus-host disease, 62% of patients who had failed to respond to corticosteroids were treated with ruxolitinib tablets and experienced significant reduction or complete disappearance of symptoms within 4 weeks, while only 39% of patients in the other treatment group had a similar response. In a second study of 329 patients with chronic graft-versus-host disease, 50% of patients who received ruxolitinib experienced improvement in symptoms after 24 weeks of treatment, compared with 26% of patients who received other optimal treatments.